Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDD-3 dendritic cell vaccine with or without peginterferon alfa-2b in resected stage II/III melanoma
2005-002636-97Phase 2Unknown
- Sponsor
- IDM Pharma
- Start
- Jul 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cutaneous melanoma (CM) comparing UVIDEM alone with UVIDEM + peginterferon alfa-2b (2 arms). Primary endpoint: Immune response to IDD-3/UVIDEM. Status: unknown.
02
Drugs
TAPCellspeginterferon alfa-2b
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2005-002636-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002636-97.